prevent thromboembolic diseases such as ischaemic stroke and myocardial infarction came from Glendale, California where a physician in charge of an all-male retirement community prescribed regular aspirin to all his patients. He argued that, since aspirin caused minor bleeding, it might prove protective against thrombotic diseases. He reported that no case of coronary or cerebral thrombosis occurred in those patients who had taken their medication throughout the 10-year study period. These observations were uncontrolled and open, and they received little attention until laboratory evidence of the inhibitory effect of aspirin on platelet aggregation was forthcoming.2 This triggered single-case studies3~4 in which individual patients with repeated attacks of amaurosis fugax attributed to retinal platelet embolism were treated with aspirin. A carotid source of emboli was assumed in two cases,3 while in the other4 the patient had thrombocythaemia. In each case, attacks ceased during treatment with aspirin, and in the cases studied by Harrison,3 the timing of recurrence after cessation of aspirin ingestion was appropriate for the known duration of the inhibitory effect of aspirin on platelet aggregation. When formal clinical trials were carried out in patients with early manifestations of cerebrovascular disease, such as transient ischaemic attacks (TIAs), or with ischaemic heart disease, many were too small for conclusive results, though most showed a reduction in endpoints such as stroke, heart attack or death of vascular origin. A metanalysis of these trials and others employing other antiplatelet agents5 shows a reduction in the risk of major thrombotic events of 20-30%.
Some of the aspirin trials reported a difference in outcome between males and females, suggesting that aspirin might only be effective as an antithrombotic agent in men. The Canadian trial of aspirin and sulphinpyrazone in patients with transient ischaemic attacks,6 for example, found that only aspirin was effective, and this apparently only in males. The risk of stroke or vascular death was reduced by 50% in males, but not significantly affected in females. An editorial in Stroke' concluded that aspirin prevented stroke in men. As a similar difference was also detected in trials of aspirin in prophylaxis against deep vein thrombosis after surgery8 and in open studies in patients with rheumatoid arthritis,9 the phenomenon did not appear to be peculiar to cerebral arterial disease, but has received most attention in this context. These clinical reports of a possible sex difference in the effectiveness of antithrombotic treatment prompt two major questions: (1) is the clinical difference real?; and (2) is there evidence from laboratory studies of an a priori reason why there might be such a difference? The answers to these questions obviously have practical implications influencing the choice of antiplatelet agent in females.
Is the clinical difference real?
The number of female patients enrolled in the clinical trials is small in comparison with that of males. There is also evidence that the disease being studied (TIA) is more benign in females. As Dykenl° pointed out in the US hospital frequency study of TIA, either stroke and death or death alone occur two to three times more often in males. In patients who were not receiving either aspirin or anticoagulants the mortality for males with TIA was 10% compared with 3% in females. The number of endpoints occurring in females may therefore be too small for reliable estimation of the impact of aspirin.
Nonetheless, the Canadian study of TIA highlighted the possibility of a sex difference, and prompted a subset analysis of the already published USA TIA trials.11,12 A further result of the debate prompted by the Canadians was the prospective stratification by sex of subsequent aspirin trials such as the UK, 13 French 14 and Danish 15 studies. Others, unfortunately, have not published separate data for males and females. 16, 17 The data available from cerebrovascular trials are set out in Tables 1-6.
The Canadian trial6 recruited men and women with TIAs or minor completed strokes and randomized them to treatment with aspirin, sulfinpyrazone, both or neither. Efficacy of the antithrombotic regimens was assessed by looking at the combined endpoints of stroke, myocardial infarction and vascular death. As sulfinpyrazone failed to affect outcome, the design was collapsed for assessment of the role of aspirin. The followup of those on aspirin or aspirin plus sulfinpyrazone revealed fewer endpoints than for those on placebo or sulfinpyrazone alone ( Table  1 ). The effect was significant in males but not in females, who made up less than a third of the patients recruited. The risk of stroke and/or death was reduced by 50% in males, but was unaffected in females.6 6 The French trial 14 included men and women with minor completed stroke or TIA and it differed from the Canadian trial in several respects. First, the majority of the patients had stroke rather than TIA; secondly, aspirin was compared with placebo either alone or in combination with dipyridamole; and, thirdly, the randomization was stratified by sex. Again males predominated ( Table 2 ). Although combined endpoints revealed an effect of aspirin with or without dipyridamole which was detectable in both sexes, stroke was only significantly reduced over the three-year period in males, as judged by the published figures. The more accurate lifetable analysis, however, looking at males and females separately, does not appear in the trials report. The Danish studyls was complicated by a high drop-out rate, but randomized males and females with TIA to aspirin or placebo. Stroke and/or death was reduced by 21% in males, but not in females (Table 3) . A small Italian study 18 recorded thromboembolic events (stroke, MI, vascular death, and recurrent TIA) in patients on aspirin Table 3 Effect of aspirin on risk of stroke and/or death after TIA (Danish study'5) and compared their incidence over two years between the sexes (Table 4 ). Males had fewer events on treatment than females, a reversal of the normal sex difference in natural history, 10 but there was no proof that females did not benefit as there was no placebo group. The two USA trials&dquo;,19 compared the effect of aspirin and placebo on the incidence of stroke or death after TIA in a medical group&dquo; and in a group undergoing carotid endarterectomy.'9 Neither study was large enough to yield a clearcut result. Only when repetitive TIAs were included as an adverse outcome was a significant difference in favour of aspirin revealed. The figures for males culled from the two publications suggest that there is more of a trend to reduced stroke/death in males than females (Table 5 ). Fields' own retrospective analysis of the data from the medical trial makes this clearer. 12 Table 5a USA aspirin trials: medical group&dquo; The UK trial, 13 like the French, randomized males and females separately. The overall impact of aspirin (either 300 or 1200 mg/day) compared with placebo was significant for a reduction in major stroke/MI/vascular death of 23%. The risk reduction was 30% for males (odds ratio 0.7, CI 0.54-0.9) compared with an increase of 10% for females (odds ratio 1.1, CI 0.69-1.76). Table 6 shows the result for stroke/MI/vascular death. Table 6 UK TIA trial 13 The collective experience of the trials that have investigated the outcome of aspirin treatment in cerebrovascular disease is summarized in Table   7 in a manner that enables a comparison to be made between male and female patients. The numbers are still small, so confidence intervals are wide. The combined experience of the Canadian and UK trials employing a combined endpoint of stroke, MI and vascular death reveals a risk reduction of 30% in males on aspirin and no benefit in females. The odds ratios are 0.7 (CL 0.56-0.86) for males and 1.14 (CL 0.78-1.65) for females. The smaller number of females enrolled is reflected in the wider confidence limits. A 20% benefit for females is not excluded by these data, therefore. When stroke and death are combined (US, UK and Danish trials), males show a risk reduction due to aspirin of 16% (odds ratio 0.84 with confidence limits of 0.65-1.08) and females a negative response (odds ratio 1.43 with confidence limits of 0.91-2.25). A metanalysis of all trials including unpublished analysis of male and female populations is being carried out by Sandercock and Peto on behalf of the Antiplatelet Trialists Collaborative Group and its results are eagerly awaited. Far more patients were entered into the cardiac than the cerebrovascular trials, and it is important that a sex difference is sought in the incidence of Table7 Summaryofefficacyofaspirincerebrovasculartrials vascular events on aspirin in this group. Pending the findings of the metanalysis there remains a suspicion that the protection afforded female patients is less clear-cut and perhaps of lesser magnitude.
Is the sex difference restricted to aspirin and to arterial disease? Table 8 summarizes the results of a small study of the effect of sulfinpyrazone on shunt patency in patients with renal failure given an arteriovenous conduit. The number of thrombi documented per patient month was reduced by this antiplatelet agent, but only in the males.2° This suggests that sex differences in thrombogenesis may be more widespread and not peculiar to aspirin. Table 8 Effect of sulfinpyrazone on arteriovenous shunt patency Harris et as randomized patients scheduled for hip surgery to aspirin or placebo and assessed the incidence of postoperative deep vein thrombosis by phlebography. Only males treated with aspirin showed a significant reduction in phlebographic abnormalities ( Table 9 ) again suggesting that the interaction between aspirin and sex is not peculiar to arterial disease. Table 9 Effect of aspirin on DVT after hip surgery8
Finally, Linos et al.9 reported their experience with patients on long-term treatment with salicylates for rheumatoid arthritis. This open study revealed that the males on aspirin apparently had a reduced risk of coronary and cerebrovascular events, whilst there was no apparent protection from vascular disease in females (Table 10 ). Little reliance can be placed on such open studies, but it raises the possibility that only male subjects may benefit from aspirin given prophylactically when they are still asymptomatic. Table 10 Effect of aspirin on risk of coronary and cerebrovascular disease in patients with rheumatoid arthritis (uncontrolled)9
Possible mechanism of a sex difference in efficacy of aspirin The increased cardiovascular mortality in males raises the obvious possibility that male platelets may be more prone to thrombus formation.
Johnson et al.2l described their finding that platelets from male rats and guinea pigs were significantly more sensitive to aggregating agents than those from females. The tenfold difference in the case of ADP was striking. Castration of male rats was subsequently found to reduce aggregability of their platelets, and the in vitro addition of testosterone (1-10ng/ml) enhanced aggregation and restored it to that of castrated animals. The effect of testosterone and other androgens was antagonized in vitro by an antiandrogen. Orchard and Botting22 could not reproduce these findings, although this might have been related to the strain and maturity of the animals used. Instead they found comparable sensitivity of male and female platelets with increases after pharmacological doses of oestrogen. Morikawa23 returned to this problem in 1985 and was again able to show an increased aggregability of male rat platelets and to relate it to the level of cyclo-oxygenase, and hence to their production of thromboxane A2 (TXA2) which promotes aggregation in response to aggregating agents like collagen.
The first studies of sex differences in human thrombogenesis related to the possible effects of the oral contraceptive and of different parts of the menstrual cycle and pregnancy. Few changes were detected that could be attributed to endogenous oestrogens. By contrast, synthetic steroids used in oral contraceptive formulations increase the relative risk of deep vein thrombosis, stroke and myocardial infarction. 24 The mechanism of this effect is poorly understood, however, with some evidence of an effect on coagulation factors25 and on some aspects of platelet function Direct comparisons of platelet aggregability by Johnson et al. 27 in 1975 showed some increased sensitivity in female donors in contrast to the same laboratory's findings in animals. However, they confirmed an enhancing effect of testosterone on aggregation in vitro that was greater than any effect of oestrogens, in parallel with their results in the rat. Testosterone increased sensitivity to collagen and arachidonic acid and to ADP when secondary release phenomena were involved. Pilo et al. 28 confirmed this last finding and produced evidence that testosterone increased lipolysis and the subsequent production of TXA2. These studies had all been carried out using methods of assessing platelet function in platelet-rich plasma.
That sex differences existed in the behaviour of human platelets in whole blood was shown by Harrison and Weisblatt.29 Aggregation in stirred whole blood was greater in males than females. This technique is thought to depend on the release of ADP from traumatized red blood cells3°, and may be affected by the presence of white cell ADPases etc. It is therefore claimed to be more 'physiological', and is analogous to the use of ADP rather than collagen in plateletrich plasma aggregometers in animal experiments. If the amount of ADP added or released from red cells is small, aggregation can occur independently of the cyclo-oxygenase pathway involved in the conversion of arachidonic acid to proaggregatory TXA2. The release reaction and activation of this pathway occur with larger amounts of ADP.
Several studies have considered whether the inhibitory effect of aspirin on cyclo-oxygenase and TXA2 production and aggregation differs in males and females in relation to the suggested differences in cyclo-oxygenase and/or platelet behaviour due to androgens or oestrogens. The first reports3l suggested that low doses of aspirin (40mg/day) inhibited aggregation in platelets from both male and female stroke patients equally, despite evidence that higher blood levels were to be expected in females. 32 Weksler, however, used a platelet-rich plasma aggregometer. When whole blood methods began to be applied sex differences were found. Thus, using impedance aggregometry in whole blood, De La Cruz,33 found that a higher dose of aspirin was needed in vitro to produce half maximal blood samples (a difference not detectable with aggregation in platelet-rich plasma). Escolar34 compared female and male blood before and after aspirin ingestion in the Baumgartner chamber. An inverted piece of animal aorta is rotated in the blood sample and the build up of platelet thrombus quantified. 150mg of aspirin taken daily for two weeks significantly reduced plateletendothelial interaction in males but not females, although thromboxane synthesis was equally blocked by acetylation of platelet cyclooxygenase. Using the aggregation of platelets in whole blood subjected to shear stress by vigorous stirring, Spranger et al. 35 also found a sex difference in the degree of inhibition produced by in vitro aspirin. The ratio of aggregation with and without aspirin was higher, indicating a greater effect of the aspirin in males (ratio of spontaneous aggregation to that inhibited by aspirin 1.54 + 0.3 for males, 1.23 + 0.22 for females, p<0.001). Male patients castrated in the course of treatment for carcinoma of the prostate showed a reduced sensitivity to aspirin, a more female-like level that was reversed by the in vitro addition of testosterone, which also increased the aspirin effect in female blood. These findings of an interaction between aspirin and testosterone (but not oestrogen) are in agreement with those of Pilo et al., 28, 36 namely, that indomethacinanother cyclo-oxygenase inhibitorcounteracted the effect of testosterone on enhanced TXA2 synthesis, and those of Uzunova et al, 36 showing that aspirin counteracted any increase in thrombus formation in endothelial damaged rat aorta caused by testosterone.
These observations suggest a possible mechanism for sex differences in platelet aggregation and aspirin efficacy. If cyclooxygenase activity is greater in males, more TXA2 will be produced, aggregation will be greater and this added aggregation will be sensitive to cyclooxygenase inhibitors such as aspirin, which will therefore have a greater effect.23 Some inspection of the Spranger data would fit with this hypothesis since the evidence is that the degree of inhibition is directly related to the magnitude of aggregation (r = 0.6, p<0.001). The decreased aspirin effect after castration parallels a reduced level of aggregation. Alternatively, cyclo-oxygenase in females might be more difficult to acetylate.33 An antiplatelet agent with a mode of action that does not involve cyclo-oxygenase (Ticlopidine) does not appear to show any sex difference in efficacy in clinical trials in cerebrovascular disease. 37 Not all the data are compatible with these simple hypotheses, however. The products of cyclo-oxygenase, such as malonaldehyde do not show sex differences. 38 The ability of aspirin to affect fibrin acretion into a thrombus in the rabbit was only seen in male animals, but MDA synthesis was equally inhibited in both sexes. Other possible mechanisms for the interaction of testosterone and aspirin should therefore be considered. Aspirin, for example, has some effects on fibrinolysis and on coagulation factors such as factor 7, and these might differ in the two sexes.
Practical considerations
The combined clinical and laboratory evidence suggests that there are interactions between sex hormones and platelet function and the effect of aspirin as an antithrombotic agent. Unless the metanalysis of all the trials removes the suspicion that aspirin is less successful in females in preventing stroke, for example, there will need to be a review of the present policy of using aspirin in all tolerant patients with cerebrovascular disease. A similar sex difference may be discerned in the case of sulfinpyrazone but the latest antiplatelet agent to undergo trial in cerebrovascular patients (Ticlopidine) showed comparable efficacy in both sexes. 37 Aspirin will probably remain the agent of choice in males because of its cheapness and known long-term safety,5 but if sex differences are confirmed it may become customary to prescribe something like Ticlopidine in females.
